EDEN PRAIRIE, Minn.,
Feb. 8, 2022 /PRNewswire/ --
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC)
("NeuroOne" or the "Company"), a medical technology company focused
on improving surgical care options and outcomes for patients
suffering from neurological disorders, today announced that it
successfully completed initial pre-clinical long-term testing of
recording capabilities on its platform thin film electrode
technology. In test procedures, the electrodes' ability to record
electrical activity over a span of 5 years was measured using an
accelerated aging test model. The test results demonstrated
NeuroOne's thin film electrodes' reliability against environmental
factors that may contribute to device failure or malfunction, which
is a well-established challenge with thin film electrode
technology.
Dave Rosa, CEO of NeuroOne
commented, "We are excited with the results of our initial
long-term testing of recording capabilities for our thin film
electrode technology. These results support the potential
expansion of utilization of these electrodes for long-term
recording for indications such as epilepsy, Parkinson's disease,
chronic back pain due to failed back surgeries, other related
neurological disorders as well as research applications. We also
believe that in the near term it may provide an opportunity to
enter the research market as well as offering the potential for
strategic licensing agreements in certain markets."
The tests performed by the Company are accelerated soak tests.
These tests are widely used in the field of neurotechnology
allowing for comparison between NeuroOne's electrodes and other
approaches in academic and industry settings. Camilo Diaz-Botia, Director of Electrode
Development for NeuroOne, said, "There are many known failure modes
of chronically implantable electrodes. For thin film devices
in particular, reliable insulation is an important challenge
because reduction of the amount of material puts electrical signals
of interest closer to detrimental factors like moisture, corrosion,
and noise, which may contribute to device malfunction or failure.
For all the tests performed at different acceleration factors, our
devices demonstrated reliable insulation, as determined by
electrochemical characterization methods, beyond 5 years of real
time use, solving one of the most significant failure modes of thin
film electrodes."
The Company also expects to release long-term data in the near
future on electrodes that would provide therapeutic stimulation for
the same applications mentioned earlier.
As previously reported, NeuroOne is also advancing a pipeline of
therapeutic electrode technologies for brain tissue ablation,
chronic stimulation use for DBS (deep brain stimulation) and spinal
cord stimulation for chronic back pain. The Company believes
these therapeutic electrode technologies are targeted to
addressable markets of over $10
billion.
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental
stage company committed to providing minimally invasive and
hi-definition solutions for EEG recording, brain stimulation and
ablation solutions for patients suffering from epilepsy,
Parkinson's disease, dystonia, essential tremors, chronic pain due
to failed back surgeries and other related neurological disorders
that may improve patient outcomes and reduce procedural costs. For
more information,
visit https://www.n1mtc.com .
Forward Looking Statements
This press release may include forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Except for statements of historical fact, any information
contained in this presentation may be a forward–looking statement
that reflects the Company's current views about future events and
are subject to known and unknown risks, uncertainties and other
factors that may cause our actual results, levels of activity,
performance or achievements to be materially different from the
information expressed or implied by these forward-looking
statements. In some cases, you can identify forward–looking
statements by the words or phrases "may," "might," "will," "could,"
"would," "should," "expect," "intend," "plan," "objective,"
"anticipate," "believe," "estimate," "predict," "project,"
"potential," "target," "seek," "contemplate," "continue, "focused
on," "committed to" and "ongoing," or the negative of these terms,
or other comparable terminology intended to identify statements
about the future. Forward–looking statements may include statements
regarding clinical and pre-clinical testing, NeuroOne's business
strategy, market size and potential growth. Although the Company
believes that we have a reasonable basis for each forward-looking
statement, we caution you that these statements are based on a
combination of facts and factors currently known by us and our
expectations of the future, about which we cannot be certain. Our
actual future results may be materially different from what we
expect due to factors largely outside our control, including risks
that our technology will not perform as expected based on results
of our pre-clinical testing; uncertainties inherent in the
development process of our technology; risks related to changes in
regulatory requirements or decisions of regulatory authorities;
risks that we may not have accurately estimated the size and growth
potential of the markets for our technology; and other risks and
uncertainties related to market and other conditions, the impact of
general economic, industry or political conditions in the
United States or internationally and those described under the
heading "Risk Factors" in our filings with the Securities and
Exchange Commission. These forward–looking statements speak only as
of the date of the podcast and the Company undertakes no obligation
to revise or update any forward–looking statements for any reason,
even if new information becomes available in the future.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neuroone-medical-technologies-corporation-releases-successful-long-term-recording-test-data-for-its-novel-thin-film-platform-electrode-technology-301476587.html
SOURCE NeuroOne Medical Technologies Corporation